Lornit Infusion, containing L-Ornithine L-Aspartate 5gm per vial, is a clinically utilized amino acid formulation indicated primarily for the management of hepatic encephalopathy and related liver dysfunctions. L-Ornithine L-Aspartate acts by enhancing the urea cycle and ammonia detoxification in the liver, thereby reducing elevated blood ammonia levels commonly observed in hepatic insufficiency. This pharmacological action helps to improve neuropsychiatric symptoms associated with hepatic encephalopathy, including confusion, altered consciousness, and cognitive impairment. Lornit Infusion is administered intravenously, allowing for rapid bioavailability and prompt therapeutic effects, particularly in acute settings. The infusion is typically employed as an adjunct to standard medical care, including dietary protein restriction and lactulose therapy, to optimize patient outcomes. It is contraindicated in patients with known hypersensitivity to its components and should be used cautiously in individuals with severe renal impairment. Adverse effects are generally mild and infrequent but may include local injection site reactions, gastrointestinal disturbances, or allergic responses. Monitoring of liver function tests and ammonia levels is recommended during therapy to assess efficacy and safety. Lornit Infusion represents a valuable therapeutic option in the supportive management of hepatic encephalopathy and other conditions associated with hyperammonemia.